Potassium News and Research

RSS

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

Mandatory cuts for salt content in processed foods on the horizon

This Tuesday The Institute of Medicine (IOM) has urged the US Food and Drug Administration to start regulating the amount of salt in processed foods. This measure according to them can do what years of advising people to cut down on salt have failed to do.

22 Apr 2010

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Salix Pharmaceuticals, Ltd. today announced that the Company will host a DDW2010 Investor Event on Monday, May 3 2010 from 9:00 p.m. to 10:00 p.m. Central Time (10:00 p.m. to 11:00 p.m. ET).

22 Apr 2010

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Icagen, Inc. today announced that results from a study of ICA-105665 in patients with photosensitive epilepsy will be presented at the Tenth Eilat Conference on New Antiepileptic Drugs on Tuesday, April 27, 2010 in Eilat, Israel. The presentation will be made by Dorothee Kasteleijn-Nolst Trenite, MD, University Medical Centre Utrecht and Universita di Roma Sapienza II, Rome, Italy.

21 Apr 2010

Nutrition experts call for sodium reduction strategies

Responding to the health threat posed by Americans' over-consumption of sodium, experts in the department of nutrition at Harvard School of Public Health (HSPH) and The Culinary Institute of America (CIA) called today for sodium reduction strategies that are strong and effective-and that maximize the enjoyment people derive from food.

21 Apr 2010

More testimony on Patel trial

In the ongoing trial of Dr. Jayant Patel for manslaughter of three men and grievous injury to the fourth during his tenure as Director of surgery at Bundaberg base hospital new testimony has surfaced. Patel had pleaded not guilty.

21 Apr 2010

Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010

Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.

20 Apr 2010

Patel trial testimony by anesthetist: bleeding and kidney damage may have led to early death

In the Jayant Patel manslaughter case new testimony has surfaced. Dr. Patel has been accused of causing the deaths of three Queensland patients and permanently injuring another when he performed operations as director of surgery at the Bundaberg Base Hospital between 2003 and 2005. He had pleaded not guilty.

20 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets 100 mg/12.5 mg, the generic version of Merck and Co., Inc.'s antihypertensive Hyzaar®.

12 Apr 2010

EDNOS categorization for young people needs to be reconsidered

Diagnostic cutoffs for anorexia nervosa and bulimia nervosa may be too strict, a study from the Stanford University School of Medicine and Lucile Packard Children's Hospital has found. Many patients who do not meet full criteria for these diseases are nevertheless quite ill, and the diagnosis they now receive, "Eating Disorder Not Otherwise Specified," may delay their ability to get treatment.

12 Apr 2010

Renal specialist says Dr Patel’s patient was too frail for surgery

In the ongoing trial of Dr Jayant Patel, Dr Peter Miach, a renal specialist, gave evidence before the Supreme Court in Brisbane. Dr Miach said the patient James Phillips had too many other problems and he would not have recommended surgery for him in his frail state.

12 Apr 2010

Blood levels of carbon dioxide may be linked to near death experiences after heart attack

Near death experiences have often been described as “seeing life flash before one’s eyes” or “intense feelings of joy and peace.” Now researchers claim that levels of Carbon Dioxide or CO2 may be the causal link for these sensations. They believe that the CO2 alters the levels of certain chemicals in the brain and makes it see lights at the ends of tunnels or dead loved ones.

9 Apr 2010

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution (with Flavor Packs), the generic version of Braintree Laboratories' NuLytely® laxative.

8 Apr 2010

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

8 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

New report assesses optimal future for REMS

Two years after the Food and Drug Administration Amendments Act of 2007 gave FDA new powers to require Risk Evaluation and Mitigation Strategies for higher risk drugs and biologics, a new report concludes that an optimal future for REMS is possible if the agency adopts a systems approach when designing REMS programs and takes advantage of new technologies -- from electronic medical records to genetic testing -- that are changing the way medicine is practiced.

5 Apr 2010

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced that it has signed a co-promotion agreement for Zipsor™ (diclofenac potassium) Liquid Filled Capsules with Ferring Pharmaceuticals Inc., a global bio-pharmaceutical company, headquartered in Switzerland.

1 Apr 2010

Research could pave way for new generation of painkillers

An international group of scientists led by Dr Nikita Gamper of the University's Faculty of Biological Sciences has discovered how two proteins play a key role in the way we feel pain, offering new targets on which drug development can be focused.

25 Mar 2010

Potassium News and Research

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Mandatory cuts for salt content in processed foods on the horizon

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Nutrition experts call for sodium reduction strategies

More testimony on Patel trial

Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010

Patel trial testimony by anesthetist: bleeding and kidney damage may have led to early death

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

EDNOS categorization for young people needs to be reconsidered

Renal specialist says Dr Patel’s patient was too frail for surgery

Blood levels of carbon dioxide may be linked to near death experiences after heart attack

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

Dalfampridine drug for multiple sclerosis now available in the U.S.

New report assesses optimal future for REMS

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Research could pave way for new generation of painkillers

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News